Continuous Positive Airway Pressure Devices Market Size & Growth Forecast 2026–2035, By Segments (Connectivity, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Continuous Positive Airway Pressure Devices Market size was worth USD 1.97 Billion in 2025 and is expected to grow at a 5.5% CAGR between 2026 and 2035, attaining USD 3.37 Billion by 2035. The industry revenue for 2026 is calculated at USD 2.06 billion.

• Base Year Value (2025): USD 1.97 Billion
• CAGR (2026-2035): 5.5%
• Forecast Year Value (2035): USD 3.37 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Continuous Positive Airway Pressure Devices Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads due to mature sleep apnea diagnosis pathways, extensive sleep clinics, and high CPAP adoption within established respiratory care systems enabling consistent recurring device demand.
  • Asia Pacific growth is driven by improving sleep disorder recognition, expanding diagnostic access, and broader availability of CPAP therapy across developing and developed healthcare systems, supporting a 6.22% CAGR.

• Segment Momentum:

  • Connected devices held a 67.18% market share in 2025 because remote therapy monitoring, adherence tracking, and device performance oversight support more consistent treatment and integrate well with routine digital care workflows.
  • Home Care Settings accounted for 58.98% of the market in 2025 and remain the fastest-growing end-use segment due to convenient long-term therapy, regular home use, and compatibility with ongoing patient monitoring.

• Market Expansion Drivers:

  • Growing prevalence of sleep apnea accelerating long-term adoption of CPAP therapy devices.
  • Expansion of home-based healthcare and remote monitoring increasing connected CPAP device utilization.
  • Rising integration of AI-enabled sleep diagnostics enhancing personalized respiratory therapy management.

• Leading Market Participants:

  Prominent companies in the continuous positive airway pressure devices market include ResMed Inc. (United States), Koninklijke Philips N.V. (Netherlands), Fisher & Paykel Healthcare Corporation Limited (New Zealand), Löwenstein Medical SE & Co. KG (Germany), Breas Medical AB (Sweden), BMC Medical Co., Ltd. (China), React Health Holdings, LLC (United States), Apex Medical Corp. (Taiwan), SEFAM Medical (France).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 1.97 Billion
  • Projected Market Size: USD 3.37 Billion by 2035
  • Growth Forecasts: 5.5% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Connected (Connectivity) | Home Care Settings (End Use)
  • Emerging Opportunity Segment: Connected (Connectivity) | Home Care Settings (End Use)

Market Growth Drivers and Industry Trends

Growing prevalence of sleep apnea accelerating long-term adoption of CPAP therapy devices

A larger diagnosed and undiagnosed patient pool is steadily driving demand for the continuous positive airway pressure devices market, particularly because sleep apnea typically requires ongoing nightly management rather than short-term intervention. As screening expands through sleep clinics, primary care referrals, and home sleep testing, more patients move into structured treatment pathways where CPAP remains a standard therapy option. This creates recurring equipment demand not only for initial device purchases but also for mask replacements, accessories, and follow-up titration, reinforcing market penetration through the chronic nature of treatment adherence and respiratory care management.

Expansion of home-based healthcare and remote monitoring increasing connected CPAP device utilization

The shift toward home-based care is strengthening market development in the continuous positive airway pressure devices market by making therapy setup, monitoring, and adherence management more practical outside traditional sleep lab settings. Connected CPAP systems allow providers, payers, and durable medical equipment suppliers to track usage, mask fit, and therapy effectiveness remotely, which supports faster intervention when patients struggle with compliance. This practical visibility is influencing market adoption of digitally enabled devices, as stakeholders increasingly prefer platforms that reduce in-person follow-up burdens while helping maintain therapy continuity in the home environment.

Rising integration of AI-enabled sleep diagnostics enhancing personalized respiratory therapy management

AI-enabled diagnostics are contributing to market size growth in the continuous positive airway pressure devices market by improving how patients are identified, stratified, and matched with therapy settings. More refined analysis of sleep patterns, respiratory events, and adherence behavior helps clinicians tailor pressure adjustments and treatment plans with greater precision, reducing trial-and-error during therapy initiation. That practical improvement in personalization supports wider use of advanced CPAP systems integrated with data platforms, as providers look for tools that can improve patient comfort, support sustained use, and make respiratory therapy management more responsive over time.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Growing prevalence of sleep apnea accelerating long-term adoption of CPAP therapy devices	2.00%	Moderate	North America, Europe	High	Near Term
Expansion of home-based healthcare and remote monitoring increasing connected CPAP device utilization	1.50%	Moderate	North America, Asia Pacific	High	Mid Term
Rising integration of AI-enabled sleep diagnostics enhancing personalized respiratory therapy management	1.00%	High	North America, Europe	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional market share in 2025 for the continuous positive airway pressure devices market, backed by established diagnosis and treatment pathways for sleep apnea, broad availability of sleep clinics, and stronger adoption of device-based therapy in routine respiratory care. The region’s leadership is aided by a mature healthcare infrastructure that enables earlier screening, higher prescription volumes, and more consistent patient access to CPAP equipment and replacement components, which keeps demand anchored in ongoing clinical use rather than one-time purchases.

Asia Pacific is projected to expand at a 6.22% CAGR over the forecast period in the continuous positive airway pressure devices market, driven by improving recognition of sleep-disordered breathing and wider access to diagnosis and therapy across major healthcare systems. Growth is accelerating as more patients enter formal treatment channels, while expanding healthcare capacity and rising availability of respiratory care devices make CPAP therapy more attainable in everyday practice across both developed and emerging markets in the region.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Emerging	Nascent
Cost-Sensitive Region	Low	Medium	Low	Medium	High
Regulatory Environment	Supportive	Neutral	Supportive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Moderate	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Moderate	Sparse	Moderate	Sparse	Sparse
Macro Indicators	Strong	Stable	Strong	Stable	Weak

Key Country Insights

United States

Home Sleep Therapy

The U.S. continuous positive airway pressure devices market is driven by expanding home-based sleep apnea management and connected healthcare services. Manufacturers are enhancing device comfort, digital monitoring, and patient adherence features to improve long-term treatment outcomes.

Japan

Patient Comfort Enhancement

Japan emphasizes compact, quiet CPAP devices that improve user comfort and encourage consistent therapy adherence. Japanese manufacturers continue refining mask designs, noise reduction, and intelligent monitoring capabilities to strengthen long-term patient engagement.

South Korea

Connected Sleep Management

South Korea is integrating CPAP devices with digital health platforms to strengthen remote patient management for sleep disorders. Healthcare providers increasingly value connected systems that enable treatment monitoring and personalized therapy adjustments through data-driven insights.

Germany

Respiratory Care Modernization

Germany is advancing CPAP adoption through established respiratory care services and increasing emphasis on effective sleep disorder management. German providers are investing in connected devices that support therapy monitoring, patient compliance, and efficient clinical follow-up.

France

Personalized Therapy Delivery

France is expanding CPAP utilization through greater focus on individualized sleep apnea treatment and long-term patient support. French healthcare providers are adopting devices with improved comfort features and digital monitoring to encourage consistent therapy use.

Italy

Clinical Care Accessibility

Italy is improving access to CPAP therapy through expanded respiratory care services and home-based treatment pathways. Italian providers are prioritizing dependable, user-friendly devices that simplify patient management while supporting effective long-term sleep apnea treatment.

Segment Leadership and Growth Trends

  Connectivity Segment Analysis: Connected (Largest & Fastest-Growing Segment)

Within the continuous positive airway pressure devices market, Connected accounted for a 67.18% share in 2025, making it the leading connectivity segment while also sustaining the strongest growth momentum. Its position is reinforced through the practical value of remote data access for therapy monitoring, adherence tracking, and device performance oversight, which helps users and care providers manage treatment more consistently. The same operating advantage is also driving continued expansion, as the continuous positive airway pressure devices market increasingly favors connected systems that fit into routine digital care workflows and support more responsive follow-up than non-connected alternatives.

End Use Segment Analysis: Home Care Settings (Largest & Fastest-Growing Segment)

By 2025, Home Care Settings held a 58.98% share in the continuous positive airway pressure devices market and remained the dominant end-use segment while also advancing at the fastest pace. This leadership reflects the routine nature of CPAP therapy, which is well suited to long-term use outside institutional environments where patients can maintain treatment continuity more conveniently. Growth continues to center in Home Care Settings because the continuous positive airway pressure devices market is increasingly shaped by demand for everyday therapy management in personal settings, where ease of access, regular use patterns, and compatibility with ongoing monitoring make home-based treatment more practical than facility-based alternatives.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Connectivity	Connected, Non-Connected	Connected	Connected
End Use	Home Care Settings, Hospitals & Clinics, Others	Home Care Settings	Home Care Settings

Competitive Landscape and Market Positioning

Prominent players in the continuous positive airway pressure devices market:

1. ResMed Inc. (United States)

2. Koninklijke Philips N.V. (Netherlands)

3. Fisher & Paykel Healthcare Corporation Limited (New Zealand)

4. Löwenstein Medical SE & Co. KG (Germany)

5. Breas Medical AB (Sweden)

6. BMC Medical Co. Ltd. (China)

7. React Health Holdings LLC (United States)

8. Apex Medical Corp. (Taiwan)

9. SEFAM Medical (France)

The continuous positive airway pressure devices market is evolving through the integration of smart monitoring capabilities and patient-friendly device designs. Manufacturers are developing quieter systems with wireless connectivity and real-time therapy tracking to improve patient compliance and treatment outcomes. Demand for home healthcare solutions and sleep disorder management technologies is additionally supporting market growth.

Competitive Dynamics and Strategic Insights
Assessment Parameter	Assigned Scale	Scale Justification
Market Concentration	High	Dominated by major players like ResMed and Philips Respironics in 2025.
M&A Activity / Consolidation Trend	Moderate	Acquisitions focus on expanding connected health and remote monitoring capabilities.
Degree of Product Differentiation	Medium	Variations in device portability and smart features, but core CPAP functionality similar.
Competitive Advantage Sustainability	Durable	Rising sleep apnea diagnoses and regulatory approvals ensure stable demand.
Innovation Intensity	High	Advances in compact designs, noise reduction, and telehealth integration in 2025.
Customer Loyalty / Stickiness	Strong	Prescription-driven purchases and brand trust drive high retention in 2025.
Vertical Integration Level	High	Major players control design, manufacturing, and distribution for quality assurance.

Industry Development/News

Company Name	Date	Key Development
ResMed	May-25	ResMed acquired VirtuOx in May 2025, an independent diagnostic testing facility, to expand its virtual care ecosystem in sleep and respiratory medicine. The acquisition strengthens access to remote diagnostic capabilities, improves integration across digital health platforms, and enhances end-to-end patient monitoring and provider connectivity in obstructive sleep apnea care pathways.
ResMed	Jan-25	ResMed introduced the AirSense 11 CPAP device in India in January 2025, incorporating Personal Therapy Assistant, Care Check-In, and connectivity with AirView and myAir platforms. The launch strengthens its footprint in a high-growth market while improving adherence, patient onboarding, and digital engagement across clinical and home-based sleep apnea treatment ecosystems.
React Health	Jun-24	React Health introduced the IntelliPAP feature across its V+Pro, V*Home, V+C, and VC+Pro ventilators in June 2024, enabling automated PEEP adjustments during noninvasive ventilation based on detected sleep-disordered breathing events. The enhancement improves adaptive therapy optimization for obstructive sleep apnea and respiratory insufficiency management in clinical and homecare ventilation settings.
ResMed	Jul-23	ResMed acquired Somnoware in July 2023, a sleep and respiratory diagnostics software provider, strengthening its digital diagnostics and workflow capabilities. The acquisition enhances integration across its device ecosystem and supports data-driven sleep apnea diagnosis, treatment planning, and coordinated care delivery through connected respiratory health platforms.
ResMed	Nov-22	ResMed opened an advanced manufacturing facility in Singapore in November 2022 to expand production capacity for AirSense 11 devices and mask systems. The facility strengthens global supply chain resilience, supports rising demand in sleep apnea therapies, and improves manufacturing scalability across its core CPAP product portfolio.
Inogen	Jan-26	Inogen launched Aurora CPAP masks in January 2026, extending its respiratory care portfolio into sleep apnea interface solutions. The introduction strengthens its positioning in the CPAP accessories segment and broadens its participation in home-based obstructive sleep apnea therapy markets through expanded patient interface offerings.
ResMed	Dec-25	ResMed secured FDA clearance in December 2025 for Smart Comfort, an AI-enabled CPAP system designed to deliver individualized therapy recommendations aimed at improving patient adherence. The clearance reinforces its digital innovation strategy and advances personalization in sleep apnea treatment through integrated device intelligence and adaptive therapy support.
SleepRes	Dec-25	SleepRes received FDA 510(k) clearance in December 2025 for the Kricket PAP device powered by Kairos Positive Airway Pressure technology. The clearance enables U.S. commercialization and introduces a new CPAP device entrant, contributing to competitive diversification within the sleep apnea treatment device market.
FDA	Aug-25	The FDA approved the Genio system in August 2025 for treating moderate to severe obstructive sleep apnea in patients with apnea-hypopnea index levels of 15–65. The approval expands treatment options beyond traditional CPAP devices, supporting adoption of neurostimulation-based therapies and broadening the competitive landscape for sleep apnea care technologies.